Trinity Biotech

Trinity Biotech Gross Profit

The Gross Profit of Trinity Biotech (TRIB) as of Nov 10, 2026 is 16.89 M USD. In the previous year, Gross Profit was 21.44 M USD — a change of -21.24% (lower).

Gross Profit

16.89 MUSD

YoY

-21.24%

Last updated:

Gross Profit of Trinity Biotech is 2025 16.89 M USD. Gross Profit of Trinity Biotech was 2024 21.44 M USD. It decreases by -21.24% lower compared to the previous year.

The Trinity Biotech Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Profit
Date
Gross Profit
Jan 1, 2018
41.45 M USD
Jan 1, 2019
38.12 M USD
Jan 1, 2020
48.58 M USD
Jan 1, 2021
33.45 M USD
Jan 1, 2022
22.05 M USD
Jan 1, 2023
19.45 M USD
Jan 1, 2024
21.44 M USD
Jan 1, 2025
16.89 M USD
The Trinity Biotech Gross Profit history
YEARGross ProfitYoY
16.89 MUSD-21.24%
21.44 MUSD+10.24%
19.45 MUSD-11.78%
22.05 MUSD-34.09%
33.45 MUSD-31.14%
48.58 MUSD+27.44%
38.12 MUSD-8.03%
41.45 MUSD-1.05%
41.89 MUSD-2.79%
43.09 MUSD-6.82%
46.25 MUSD-8.15%
50.35 MUSD+9.66%
45.91 MUSD+8.66%
42.25 MUSD+5.30%
40.13 MUSD-8.69%
43.95 MUSD-22.93%
57.02 MUSD-8.77%
62.49 MUSD+13.11%
55.25 MUSD+8.79%
50.78 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Revenue

Trinity Biotech Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
90.44 M USD
872,000.00 USD
-4.07 M USD
Jan 1, 2020
101.98 M USD
82,000.00 USD
-6.39 M USD
Jan 1, 2021
81.15 M USD
3.94 M USD
875,000.00 USD
Jan 1, 2022
62.52 M USD
-15.27 M USD
-41.00 M USD
Jan 1, 2023
56.83 M USD
-27.05 M USD
-24.02 M USD
Jan 1, 2024
61.56 M USD
-21.17 M USD
-31.79 M USD
Jan 1, 2025
43.79 M USD
-11.42 M USD
-37.38 M USD
Jan 1, 2026 (e)
59.50 M USD
-9.31 M USD
-385.00 M USD

Trinity Biotech Margins

Trinity Biotech stock margins

The Trinity Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Trinity Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Trinity Biotech.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
42.15 %
0.96 %
-4.50 %
Jan 1, 2020
47.64 %
0.08 %
-6.26 %
Jan 1, 2021
41.23 %
4.85 %
1.08 %
Jan 1, 2022
35.26 %
-24.42 %
-65.58 %
Jan 1, 2023
34.22 %
-47.59 %
-42.26 %
Jan 1, 2024
34.83 %
-34.38 %
-51.64 %
Jan 1, 2025
38.57 %
-26.07 %
-85.36 %
Jan 1, 2026 (e)
38.57 %
-15.64 %
-647.06 %

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Gross Profit of Trinity Biotech is 16.89 M USD in 2025.

Gross Profit of Trinity Biotech changed from 21.44 M USD to 16.89 M USD, representing a -21.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.

Gross Profit's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's Trinity Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Trinity Biotech

All Key Metrics — Trinity Biotech